NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Ahh, but that is not what happened. Endpoints were changed, which happens, we have discussed it before for big pharma trials in the past, even where one BP had to throw out their previously granted Special Protocol Assessment to change the endpoints during a trial.

PFS is only a proxy for survival. As it was as a measure at the time of the trial, it was clearly NOT a valid surrogate measure for Ongoing Survival. The trial did not fail in any way on the basis of survival and in this case, as to PFS, the measure itself failed, not the trial. It failed to be a valid proxy for survival.